全文获取类型
收费全文 | 213624篇 |
免费 | 50593篇 |
国内免费 | 3702篇 |
专业分类
耳鼻咽喉 | 2490篇 |
儿科学 | 7231篇 |
妇产科学 | 3981篇 |
基础医学 | 39265篇 |
口腔科学 | 9248篇 |
临床医学 | 22301篇 |
内科学 | 37381篇 |
皮肤病学 | 6163篇 |
神经病学 | 24467篇 |
特种医学 | 8245篇 |
外国民族医学 | 27篇 |
外科学 | 22138篇 |
综合类 | 15934篇 |
现状与发展 | 16篇 |
一般理论 | 39篇 |
预防医学 | 18209篇 |
眼科学 | 3956篇 |
药学 | 21191篇 |
90篇 | |
中国医学 | 7839篇 |
肿瘤学 | 17708篇 |
出版年
2024年 | 193篇 |
2023年 | 1427篇 |
2022年 | 2475篇 |
2021年 | 5316篇 |
2020年 | 9227篇 |
2019年 | 14402篇 |
2018年 | 13839篇 |
2017年 | 15139篇 |
2016年 | 14327篇 |
2015年 | 14260篇 |
2014年 | 16465篇 |
2013年 | 18897篇 |
2012年 | 15802篇 |
2011年 | 16307篇 |
2010年 | 13876篇 |
2009年 | 10057篇 |
2008年 | 10569篇 |
2007年 | 9158篇 |
2006年 | 8523篇 |
2005年 | 7870篇 |
2004年 | 7294篇 |
2003年 | 6769篇 |
2002年 | 5872篇 |
2001年 | 4868篇 |
2000年 | 3394篇 |
1999年 | 2117篇 |
1998年 | 1767篇 |
1997年 | 1702篇 |
1996年 | 1579篇 |
1995年 | 1512篇 |
1994年 | 1290篇 |
1993年 | 1143篇 |
1992年 | 1045篇 |
1991年 | 942篇 |
1990年 | 837篇 |
1989年 | 763篇 |
1988年 | 601篇 |
1987年 | 495篇 |
1986年 | 518篇 |
1985年 | 810篇 |
1984年 | 735篇 |
1983年 | 474篇 |
1982年 | 595篇 |
1981年 | 476篇 |
1980年 | 450篇 |
1979年 | 319篇 |
1978年 | 289篇 |
1977年 | 234篇 |
1976年 | 226篇 |
1975年 | 154篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
43.
《Journal of the American College of Radiology》2020,17(10):1207-1219
PurposeLobular neoplasia (LN) detected on breast core needle biopsy is frequently managed with surgical excision because of concern for undersampled malignancy. The authors performed a systematic review and meta-analysis to estimate the risk for upgrade to malignancy in the setting of imaging-concordant classic LN diagnosed on core biopsy.MethodsPubMed and Embase were searched for original articles published from 1998 to 2020 that reported rates of upgrade to malignancy for classic LN, including atypical lobular hyperplasia (ALH) and classic lobular carcinoma in situ (LCIS). Two reviewers extracted study data and assessed the following quality criteria: exclusion of variant LCIS, exclusion of imaging-discordant lesions, and outcome reporting for ≥70% of lesions. For studies meeting all criteria, pooled risks for upgrade to any malignancy (invasive carcinoma or ductal carcinoma in situ) and invasive malignancy for all LN, ALH, and LCIS were estimated using random-effects models.ResultsFor 65 full-text articles included in the review, the risk for upgrade to any malignancy ranged from 0% to 45%. Among the 16 studies that met all quality criteria for the meta-analysis, pooled risks for upgrade to any malignancy were 3.1% (95% confidence interval [CI], 1.8%-5.2%) for all LN, 2.5% (95% CI, 1.6%-3.9%) for ALH, and 5.8% (95% CI, 2.9%-11.3%) for LCIS. Risks for upgrade to invasive malignancy were 1.3% (95% CI, 0.7%-2.4%) for all LN, 0.4% (95% CI, 0.0%-4.2%) for ALH, and 3.5% (95% CI, 2.0%-5.9%) for LCIS.ConclusionsThe risk for upgrade to malignancy for LN found on breast biopsy is low. Imaging surveillance can likely be offered as an alternative to surgical management for LN, particularly for ALH. 相似文献
44.
《Journal of endodontics》2020,46(10):1455-1464
IntroductionThe aim of this study was to investigate whether mineral trioxide aggregate (MTA) can be modified with caffeic acid (CA) to form caffeic acid/mineral trioxide aggregate (CAMTA) cement and to evaluate its physicochemical and biological properties as well as its capability in immune suppression and angiogenesis.MethodsMTA was immersed in trishydroxymethyl aminomethane buffer with CA to allow coating onto MTA powders. X-ray diffractometry and tensile stress-strain tests were conducted to assess for physical characteristics of CAMTA and to evaluate for successful modification of MTA. Then, the CAMTA cement was immersed in simulated body fluid to evaluate its hydroxyapatite formation capabilities and Si release profiles. In addition, RAW 264.7 cells and human dental pulp stem cells were used to evaluate CAMTA’s immunosuppressive capabilities and cell responses, respectively. hDPSCs were also used to assess CAMTA’s angiogenic capabilities.ResultsThe X-ray diffractometry results showed that CA can be successfully coated onto MTA without disrupting or losing MTA’s original structural properties, thus allowing us to retain the initial advantages of MTA. CAMTA was shown to have higher mechanical properties compared with MTA and had rougher pitted surfaces, which were hypothesized to lead to enhanced adhesion, proliferation, and secretion of angiogenic- and odontogenic-related proteins. In addition, it was found that CAMTA was able to enhance hydroxyapatite formation and immunosuppressive capabilities compared with MTA.ConclusionsCAMTA cements were found to have improved physicochemical and biological characteristics compared with their counterpart. In addition, CAMTA cements had enhanced odontogenic, angiogenic, and immunosuppressive properties compared with MTA. All of the results of this study proved that CAMTA cements could be a biomaterial for future clinical applications and tissue engineering use. 相似文献
45.
Cost‐Effectiveness and Cost‐Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study
下载免费PDF全文
![点击此处可从《Neuromodulation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Furio Zucco MD Roberta Ciampichini MSc Angelo Lavano MD Amedeo Costantini MD Marisa De Rose MD Paolo Poli MD Gianpaolo Fortini MD Laura Demartini MD Enrico De Simone MD Valentino Menardo MD Piero Cisotto MD Mario Meglio MD Luciana Scalone PhD Lorenzo G. Mantovani DSc 《Neuromodulation》2015,18(4):266-276
46.
47.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
48.
49.
50.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献